A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.

Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...

Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

Israeli scientists have identified a promising new factor in the pathology of Parkinson’s disease that could pave the way for ...

In addition, they often have milder symptoms, especially in the early stages ... could be a promising candidate diagnostic ...

Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.

Treatments targeting alpha-synuclein aggregation account for 26% of the 7MM' pipeline disease-modifying therapies for ...

The research focus on improving non-motor symptoms in PD patients is also highlighted. (Image Credits: Pixabay) Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving ...

The Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective ...

The following column was originally published on Feb. 25, 2022. Thanks to breakthroughs in medicine and nutrition in recent years, we are living longer than ever before. But this increase in life ...